FDA Special Protocol Assessments Illuminate Evolution Of Cancer Endpoints
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s special protocol assessment process is being used overwhelmingly for cancer programs, with more than half of pivotal trial SPAs going to oncologics.
You may also be interested in...
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product